Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-55 With Peanut Allergy
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This study is a two-part Phase 1b/2a First-in-Human (FIH) randomized, double-blind,
placebo-controlled clinical trial to assess the safety, tolerability, pharmacodynamics, and
efficacy of multiple ascending doses of CNP-201 in Part A, with the goal of identifying a
safe and tolerable dose level to be evaluated further in a larger number of subjects in Part
B.